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smoking cessation: an observational study using the Clinical
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Foundation Trust, University of Bristol, Bristol, UK
5Department of Psychology, University of Bath, Bath, UK
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7National Institute for Health Research Collaboration for Leadership in Applied Health Research and
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8Department of Economics, University of Bristol, Bristol, UK
*Corresponding author neil.davies@bristol.ac.uk
Background: Smoking is the leading avoidable cause of illness and premature mortality. The first-line
treatments for smoking cessation are nicotine replacement therapy and varenicline. Meta-analyses of
experimental studies have shown that participants allocated to the varenicline group were 1.57 times
(95% confidence interval 1.29 to 1.91 times) as likely to be abstinent 6 months after treatment as
those allocated to the nicotine replacement therapy group. However, there is limited evidence about
the effectiveness of varenicline when prescribed in primary care. We investigated the effectiveness and
rate of adverse events of these medicines in the general population.
Objective: To estimate the effect of prescribing varenicline on smoking cessation rates and health
outcomes.
Data sources: Clinical Practice Research Datalink.
Methods: We conducted an observational cohort study using electronic medical records from the
Clinical Practice Research Datalink. We extracted data on all patients who were prescribed varenicline
or nicotine replacement therapy after 1 September 2006 who were aged ≥ 18 years. We investigated
the effects of varenicline on smoking cessation, all-cause mortality and cause-specific mortality and
hospitalisation for: (1) chronic lung disease, (2) lung cancer, (3) coronary heart disease, (4) pneumonia,
(5) cerebrovascular disease, (6) diabetes, and (7) external causes; primary care diagnosis of myocardial
infarction, chronic obstructive pulmonary disease, depression, or prescription for anxiety; weight in kg;
general practitioner and hospital attendance. Our primary outcome was smoking cessation 2 years
after the first prescription. We investigated the baseline differences between patients prescribed
varenicline and patients prescribed nicotine replacement therapy. We report results using
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multivariable-adjusted, propensity score and instrumental variable regression. Finally, we developed
methods to assess the relative bias of the different statistical methods we used.
Results: People prescribed varenicline were healthier at baseline than those prescribed nicotine
replacement therapy in almost all characteristics, which highlighted the potential for residual
confounding. Our instrumental variable analysis results found little evidence that patients prescribed
varenicline had lower mortality 2 years after their first prescription (risk difference 0.67, 95% confidence
interval –0.11 to 1.46) than those prescribed nicotine replacement therapy. They had similar rates
of all-cause hospitalisation, incident primary care diagnoses of myocardial infarction and chronic
obstructive pulmonary disease. People prescribed varenicline subsequently attended primary care less
frequently. Patients prescribed varenicline were more likely (odds ratio 1.46, 95% confidence interval
1.42 to 1.50) to be abstinent 6 months after treatment than those prescribed nicotine replacement
therapy when estimated using multivariable-adjusted for baseline covariates. Patients from more
deprived areas were less likely to be prescribed varenicline. However, varenicline had similar
effectiveness for these groups.
Conclusion: Patients prescribed varenicline in primary care were more likely to quit smoking than
those prescribed nicotine replacement therapy, but there was little evidence that they had lower rates
of mortality or morbidity in the 4 years following the first prescription. There was little evidence of
heterogeneity in effectiveness across the population.
Future work: Future research should investigate the decline in prescribing of smoking cessation
products; develop an optimal treatment algorithm for smoking cessation; use methods for using
instruments with survival outcomes; and develop methods for comparing multivariable-adjusted and
instrumental variable estimates.
Limitations: Not all of our code lists were validated, body mass index and Index of Multiple Deprivation
had missing values, our results may suffer from residual confounding, and we had no information on
treatment adherence.
Trial registration: This trial is registered as NCT02681848.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 9. See the NIHR Journals Library website for further project information.
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Plain English summary
Smoking is the number one avoidable cause of ill health and death. Experiments suggest that moresmokers will quit after being given the drug varenicline than with any other smoking cessation
treatment. However, most of the experiments used to license varenicline had a relatively short follow-up
(< 1 year) and did not necessarily recruit participants who were representative of smokers seen in a
general practice in the UK, who tend to be older, are sicker and more likely to have neuropsychiatric
illnesses.
In this study, we investigated the outcomes of 287,079 patients prescribed varenicline or nicotine
replacement therapy (e.g. nicotine patches and gum). We followed each patient for up to 4 years after
they received their prescriptions and matched their data to information on deaths from the Office for
National Statistics and hospital admissions. We investigated how often these patients subsequently
attended their general practitioner, and how often they received a diagnosis of myocardial infarction,
chronic obstructive pulmonary disease, depression or anxiety in primary care.
We found that patients who were prescribed varenicline were much more likely to quit smoking
up to 4 years after they received treatment and subsequently attended their general practitioner
less frequently. These findings were robust across the three different analysis methods we used.
We also found that patients prescribed varenicline were much less likely to be ill or to die than those
prescribed nicotine replacement therapy. However, these results may be because the patients who
were prescribed varenicline were much healthier before they received the prescription. Therefore,
these differences in health are unlikely to be caused by taking varenicline or quitting smoking.
In conclusion, varenicline helped patients quit smoking, but there was little causal evidence that
prescribing patients varenicline causally reduced rates of mortality or morbidity compared with
prescribing nicotine replacement therapy.
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Scientific summary
Background
Smoking is the major avoidable cause of preventable morbidity and mortality in the UK and internationally.
Smoking is also the principal cause of health inequalities and is responsible for most of the difference in
healthy life expectancy between the richest and poorest in our society and those with and without mental
health problems. Studies have estimated that smoking-related illnesses cost the NHS approximately £5B
per year. Varenicline is the most clinically effective smoking cessation medicine for short-term abstinence
in randomised controlled trials. However, there is relatively little evidence for its long-term effectiveness
and impact on clinical outcomes that are relevant to the NHS.
Concerns have been raised that varenicline is associated with a higher risk of adverse events, particularly
psychiatric morbidity, including suicide, self-harm and cardiovascular events, than other smoking cessation
interventions. These concerns led the Food and Drug Administration to issue black box warnings about the
possible adverse effects of varenicline from July 2009 to December 2016. The Medicines and Healthcare
products Regulatory Agency also issued warnings; however, the observational studies that provided most
of the evidence about the potential adverse effects of varenicline are prone to residual confounding.
To address this gap in the literature, we investigated the adverse and beneficial effects of prescribing
varenicline and nicotine replacement therapies using three statistical approaches to overcome confounding:
multivariable-adjusted regression, propensity score regression and instrumental variable analysis.
We investigated the effects of varenicline on all-cause mortality and smoking abstinence, as well as
on all-cause primary and secondary care use because smoking increases morbidity and imposes major
costs on health-care services. We examined differences in smoking cessation medication effectiveness
by socioeconomic position because a systematic review reported that NHS stop-smoking services
might be helping to reduce inequalities in smoking prevalence by preferentially targeting smokers of
lower socioeconomic position.
Objectives
l To investigate the long-term smoking abstinence of patients prescribed either varenicline or
nicotine replacement therapies in the Clinical Practice Research Datalink and whether or not the
effects differ by area-level deprivation.
l To investigate the causal effects of prescribing smoking cessation therapies on:
¢ all-cause mortality and death due to chronic lung disease, lung cancer, coronary heart disease,
pneumonia, cerebrovascular disease, diabetes and external causes
¢ all-cause and incident cause-specific hospitalisation (specifically chronic lung disease, lung
cancer, coronary heart disease, pneumonia, cerebrovascular disease, diabetes and
external causes)
¢ frequency of general practice and hospital attendance
¢ incident primary care diagnosis of respiratory illness
¢ incident primary care diagnosis of myocardial infarction
¢ incident primary care diagnosis of depression or anxiety
¢ weight in kg
¢ incident registration of (1) any malignant neoplasm and (2) lung malignancy.
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Methods
The data
We used an extract of data from the Clinical Practice Research Datalink. This data set is a nationally
representative database of electronic medical records in the UK.
Data extraction
We extracted all smokers aged ≥ 18 years who were prescribed smoking cessation treatment [see Joint
Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press.
URL: www.medicinescomplete.com (accessed January 2020), chapter 4.10.2] in ‘up to standard’ primary
care centres contributing to the Clinical Practice Research Datalink after introduction of varenicline in
the UK on 1 September 2006. Up to standard practices are practices that provided consistent data to
the Clinical Practice Research Datalink. Inclusion criteria included having an ‘acceptable’ record and
having at least 1 year of registration at their practice before their first smoking cessation prescription
to allow for high-quality assessment of confounders. Patients’ records are defined as acceptable for
research purposes if they registered with a practice with valid data, including on sex and age. There
were 220,136 eligible patients.
Intervention
The intervention was the first prescription of varenicline within the eligible period, and the control
treatment was nicotine replacement therapy. We focus on the first recorded treatment because
subsequent treatment decisions are likely to be highly non-random.
Follow-up
Follow-up started on the date of the first prescription and ended on an event or the end of follow-up
owing to mortality or end of registration.
Outcomes
We assessed each outcome at 3, 6, 9, 12, 24 and 48 months after the first prescription.
Smoking cessation
We defined smoking cessation using general practitioner records that indicated the patients’ smoking
status. Each patient had multiple records that stated their smoking status, which can be indicated as
current, former or never smoker. General practitioners were incentivised to record their patients’
smoking status.
Mortality
We defined mortality using the linked Office for National Statistics mortality data. This data set gave
the date and primary causes of death. We investigated the following secondary outcomes: mortality
due to chronic lung disease [International Statistical Classification of Diseases and Related Health Problems,
Tenth Revision (ICD-10) codes = J40–44], lung cancer (ICD-10 code = C34), coronary heart disease
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(ICD-10 codes = I21–25), pneumonia (ICD-10 codes = J12–18), cerebrovascular disease (ICD-10 codes
= I60–69), diabetes (ICD-10 codes = E10–14) and external causes (ICD-10 codes = V01–Y98).
Hospitalisation
We identified episodes of hospitalisation using the linked Hospital Episode Statistics data set. This data
set provides the date and cause of hospitalisation for all linked patients. We investigated both all-cause
hospitalisation and cause-specific hospitalisation using the codes described above for mortality.
Primary care diagnosis and attendance
Primary care diagnoses of myocardial infarction, chronic obstructive pulmonary disease, depression and
anxiety were identified using validated code lists. The frequency with which each patient attended
primary care was identified from their records.
Weight
The patients’ weight in the months following treatment was identified using their electronic medical
records.
Diagnosis of depression or prescriptions for anxiety
Subsequent diagnosis of depression and prescriptions for hypnotics or anxiolytics were identified using
diagnosis codes and prescription records in the 4 years after their first prescription.
Potential confounders
The potential confounders measured at baseline were age; body mass index; alcohol drug misuse, defined
using Read codes; socioeconomic position measured by the Index of Multiple Deprivation; an indicator
for having more than five primary care consultations in the year before first prescription; indicators for
year of prescription; any previous prescriptions of hypnotics; any previous prescriptions of antipsychotics;
any previous prescriptions of antidepressants; diagnoses of self-harm; diagnoses of myocardial infarction;
diagnoses of chronic obstructive pulmonary disease; any psychiatric disease; and any serious comorbidity
(a non-zero Charlson Comorbidity Index). We accounted for missing data by using imputation by chained
equations, because some patients were missing body mass index and socioeconomic position data.
Statistical methods
We estimated the effects of varenicline and nicotine replacement therapy using three statistical methods:
multivariable-adjusted logistic regression, propensity score matched regression and instrumental variable
regression.We did not use Cox survival models because the proportional hazards assumption did not
hold. Our basic adjusted models adjust for sex, year of first prescription and age. Our fully adjusted
results also adjust for all confounders described above. We used propensity score and the covariates
described above to match patients treated with varenicline to other similar patients prescribed nicotine
replacement therapy using one-to-one matching with no calliper. There was a complete overlap in the
propensity scores between patients prescribed varenicline and nicotine replacement therapy. The
propensity score depends on similar assumptions to multivariable-adjusted regression (conditional
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exchangeability). Both approaches could suffer from residual confounding.We used instrumental
variable analysis to address this residual confounding.
Instrumental variable analysis requires a variable, the ‘instrument’ that is defined by three assumptions:
that the instrument (1) associates with the treatment of interest, (2) is not associated with observed or
unobserved potential confounding factors and (3) does not directly affect the outcome. A widely used
instrument in pharmacoepidemiology is physicians’ prescribing preferences for different medications.
We cannot directly measure general practitioners’ preferences, so we used the prescriptions to their
previous seven patients seen before the index patient as a proxy for their preferences. We investigated
whether or not the instrumental variable assumptions held by (1) testing the association of their prior
prescription with their subsequent prescriptions and (2) investigating the association with potential
confounders. We estimated the effects of varenicline and nicotine replacement therapy using additive
structural models for binary outcomes and two-stage least squares for continuous outcomes.
All standard errors account for the clustering of patients at the practice level.
Results
We sampled 287,079 patients who were prescribed smoking cessation medications; of these, 70,610
patients received a varenicline prescription and 149,526 received a nicotine replacement therapy
prescription. These patients were used to estimate the effect of smoking cessation medication on
smoking cessation. A subset of 126,718 patients had data linked to the Hospital Episode Statistics data
set, of whom 41,742 received a varenicline prescription and 84,976 received a nicotine replacement
therapy prescription. On average, patients prescribed varenicline were healthier in almost every way
than those prescribed nicotine replacement therapy. They were younger, less likely to have comorbidities
or neuropsychiatric conditions and were less likely to be prescribed other medications. Our primary
outcome was smoking cessation 2 years after the first prescription. In the full results, we present the
estimates for 3, 6, 9, 12, 24 and 48 months. The results described in this summary all relate to 24 months
after the first prescription.
Smoking cessation
Two years after their first prescription, 28.8% of patients prescribed varenicline had quit, compared
with 24.3% of patients prescribed nicotine replacement therapy. After adjustment for sex, age and
year of prescription, using multivariable regression, patients prescribed varenicline were 30% (95%
confidence interval 27% to 33%) more likely than patients prescribed nicotine replacement therapy
to be non-smokers at 2 years. This difference fell to 26% (95% confidence interval 23% to 29%) after
adjustment for all the potential confounders. There was little evidence of differences by socioeconomic
deprivation. The propensity score matched and instrumental variable regression suggested similar
differences in effectiveness. These results are comparable to the effects observed in meta-analyses of
randomised controlled trials. Our estimates suggested that 4.76 (95% confidence interval 2.77 to 6.74)
additional patients would be expected to quit within 2 years per 100 patients prescribed varenicline
rather than nicotine replacement therapy.
Mortality
Patients prescribed varenicline had lower mortality than those prescribed nicotine replacement therapy.
For every 100 patients prescribed varenicline rather than nicotine replacement therapy, there were
1.33 (95% confidence interval 1.11 to 1.55) fewer deaths. This difference fell to 1.20 (95% confidence
interval 0.97 to 1.44) after adjustment for baseline covariates using multivariable-adjusted regression.
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Patients prescribed varenicline had lower cause-specific mortality, including 0.25 (95% confidence
interval 0.16 to 0.33) fewer lung cancer deaths per 100 patients within 2 years of their first prescription.
These differences modestly attenuated after adjustment for baseline covariates; however, the baseline
differences between individuals could explain relatively little of the observed differences in mortality.
In contrast, there was little evidence from the instrumental variable analysis that patients prescribed
varenicline had lower mortality (risk difference per 100 patients prescribed = –0.67, 95% confidence
interval –1.46 to 0.11). There was little consistent evidence from the instrumental variable analysis
of effects on cause-specific mortality. In particular, there were similar rates of lung cancer mortality
(risk difference = 0.00, 95% confidence interval –0.27 to 0.26).
Hospitalisation
Patients prescribed varenicline were less likely to be hospitalised (risk difference = 6.33, 95% confidence
interval 5.60 to 7.07). After adjustment for baseline covariates using multivariable-adjusted regression,
this difference fell (risk difference = 1.20, 95% confidence interval 0.97 to 1.44). These differences
were primarily due to chronic lung disease, pneumonia, cardiovascular disease and external causes.
The instrumental variable estimates provided little evidence that varenicline reduced hospitalisation,
but they were imprecise.
Primary care diagnosis and attendance
Patients prescribed varenicline were less likely to receive a primary care diagnosis of myocardial
infarction or chronic obstructive pulmonary disease (risk difference = 0.14, 95% confidence interval
0.03 to 0.26, and 0.65, 95% confidence interval 0.35 to 0.94, respectively). The baseline covariates
using multivariable-adjusted regression explained a proportion of these differences. The instrumental
variable estimates provided little evidence that varenicline caused these reductions in diagnoses of
myocardial infarctions and chronic obstructive pulmonary disease. Patients prescribed varenicline
attended primary care 14.37% (95% confidence interval 12.19% to 16.50%) less frequently. This
difference fell to 4.29% (95% confidence interval 3.31% to 4.73%) after adjustment for covariates
using multivariable-adjusted regression. The instrumental variable analysis suggested that varenicline
caused a 19.49% (95% confidence interval 11.11% to 27.09%) drop in primary care attendance.
Weight
Patients who were prescribed varenicline were 1.28 kg (95% confidence interval 0.92 to 1.63 kg)
heavier 2 years after the first prescription than patients prescribed nicotine replacement therapy. This
difference attenuated after adjustment for baseline covariates using multivariable-adjusted regression
(mean difference = 1.06 kg, 95% confidence interval 0.84 to 1.29 kg). The instrumental variable analysis
implied that varenicline caused a similar 1.14-kg (95% confidence interval 0.09 to 2.20 kg) increase in
weight after 2 years.
Limitations
A limitation of this study is that we used observational data from electronic medical records and did not
randomise individuals to treatment. This issue means that we cannot be certain that the assumptions on
which our analysis depends hold. Furthermore, for many of the outcomes, we had a limited number of
events and, thus, limited power and precision. This issue may have limited our ability to detect effects on
the outcomes.
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Conclusions and recommendations
Implications for health care
Patients who were prescribed varenicline were substantially more likely to be non-smokers up to
4 years later than those who were prescribed nicotine replacement therapy. These differences were
robust across different statistical methods. However, we found relatively little evidence that patients
prescribed varenicline had substantially improved health outcomes in the 4 years following their
first prescription. There was some evidence from multivariable-adjusted regression of lower mortality
and morbidity. However, our instrumental variable results suggest that this is likely to be because of
residual confounding. The instrumental variable results were less precise than the multivariable-adjusted
regression results. However, the results were inconsistent with the health improvements seen in the
conventional analysis. Across all analyses, patients prescribed varenicline were more likely to experience
weight gain and had lower subsequent primary care attendance.
Recommendations for future research
Varenicline is both efficacious, as indicated by randomised trials, and effective in real-world settings.
In line with national prescribing trends, there is some evidence that prescribing of varenicline has
fallen substantially over the period we studied. These trends may be because of concerns over
the adverse event profile, or more likely because of the increasing prevalence of e-cigarettes and
outsourcing of smoking cessation services to local councils. Further information is needed about the
longer-term effects of smoking cessation. The vast majority of longer-term evidence of the effects
of quitting smoking comes from observational studies. If healthier and more health-conscious people
are more likely to attempt to quit smoking, then these studies may overstate the benefits of quitting.
More research is needed about the reversibility of the health impacts of smoking, using research
methods that can overcome residual confounding.
Trial registration
This trial is registered as NCT02681848.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 9.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Smoking is the major avoidable cause of preventable morbidity and mortality in the UK andinternationally.1,2 Smoking is also the principal cause of health inequalities and is responsible for
most of the difference in healthy life expectancy between the richest and poorest in our society3 and
those with and without mental health problems.4 Studies have estimated that smoking-related illnesses
cost the NHS approximately £5B per year.5 In 1974, 45.6% of the population smoked; by 2016, this
had fallen to 16.1% (Figure 1).
The main form of smoking cessation treatment is nicotine replacement therapy (NRT), such as nicotine
patches and gums. Pharmaceutical treatments for nicotine addiction include bupropion and varenicline;
however, bupropion is rarely used.7 Varenicline, a nicotinic receptor partial agonist, has been available in
the UK from 2006. Varenicline has been shown to be the most effective smoking cessation medicine for
short-term abstinence in randomised controlled trials (RCTs).7 However, there is relatively little evidence
for its long-term effectiveness and impact on clinical outcomes that are relevant to health-care providers.
In addition, concerns have been raised that smokers taking varenicline have a higher risk of adverse
events, including suicide, self-harm and cardiovascular events, than with other smoking cessation
interventions.8 This led the Food and Drug Administration (FDA) to issue black box warnings about the
possible adverse effects of varenicline between July 2009 and December 2016.9 There have been large
randomised studies comparing the effectiveness and safety of varenicline with NRT, such as (EAGLES
Evaluating Adverse Events in a Global Smoking Cessation Study).10 However, much of the evidence about
the potential adverse effects of varenicline comes from observational studies that are prone to residual
confounding. Furthermore, the experimental evidence about the effects of prescribing varenicline on
health outcomes has limited follow-up.
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FIGURE 1 Proportion of the adult population in Great Britain who smoke, by age. Estimates from the Annual Population
Survey and published by the Office for National Statistics.6
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The rationale for this study
We addressed this gap in the literature by investigating the adverse and beneficial effects of prescribing
varenicline and NRTs using three statistical approaches to overcome confounding: multivariable adjusted,
propensity score matched and instrumental variable regression. We investigated the effects of varenicline
on all-cause mortality and smoking abstinence, and on all-cause primary and secondary care use because
smoking increases morbidity and imposes major costs on health-care services.11 We examined the
differences in smoking cessation medication effectiveness by socioeconomic position (SEP) because a
recent systematic review reported that UK stop-smoking services might be helping to reduce inequalities
in smoking prevalence by preferentially targeting smokers of lower SEP.12
INTRODUCTION
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Chapter 2 Methods
Parts of this text have been reproduced from Davies et al.
13 Published by the BMJ Publishing
Group Limited. For permission to use (where not already granted under a licence) please go to
http://www.bmj.com/company/products-services/rights-and-licensing/. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Research objectives
l To investigate the long-term smoking abstinence of patients prescribed either varenicline or NRTs in
the Clinical Practice Research Datalink (CPRD) and whether or not the effects differ by area-level
deprivation.
l To investigate the causal effects of prescribing smoking cessation therapies on:
¢ all-cause mortality and death due to chronic lung disease, lung cancer, coronary heart disease,
pneumonia, cerebrovascular disease, diabetes and external causes
¢ all-cause and incident cause-specific hospitalisation (specifically chronic lung disease, lung cancer,
coronary heart disease, pneumonia, cerebrovascular disease, diabetes and external causes)
¢ incident primary care diagnosis of respiratory illness
¢ incident primary care diagnosis of myocardial infarction
¢ incident primary care prescription of a hypnotic or anxiolytic
¢ the frequency of attendance at a general practice or a hospital
¢ weight in kg
¢ incident registration of (1) any malignant neoplasm and (2) lung malignancy.
Study design
This was a prospective longitudinal cohort study of electronic medical records of patients prescribed
smoking cessation treatments in primary care. The CPRD’s Independent Scientific Advisory Committee
approved this study (protocol number 15_107). The protocol has been published.13
Data extraction
We extracted data from patients aged ≥ 18 years who were prescribed smoking cessation treatment
(see British National Formulary, chapter 4.10.214) in ‘up to standard’ primary care centres contributing
to the CPRD after 1 September 2006, when varenicline became available in the UK. ‘Up to standard’
practices are those that provided consistent data to the CPRD. Inclusion criteria included having an
‘acceptable’ record and having at least 1 year of registration at their practice before their first smoking
cessation prescription to allow for high-quality assessment of confounders. The CPRD defines patients’
data as acceptable if they have valid information, including information regarding age and sex.15 The
CPRD linked data from the Office for National Statistics (ONS) mortality records and the Hospital
Episode Statistics for around half of the practices in the study. We defined the health outcomes mainly
from these linked data sets. For this reason, we restricted the evaluation of the health impact of
smoking cessation treatments to linked practices. Figure 2 shows a flow chart of the inclusion and
exclusion of patients for the effectiveness and morbidity and mortality aspects of the study.
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Excluded from analysis owing to protocol restrictions
Records Patients
Patient's maximum age was 15 years at time of prescription 670 0
Patient was prescribed smoking cessation medication after
registration period 
242 0
Smoking cessation medication was prescribed before
registration period  
53,294 0
Patient was aged 16 or 17 years at the time of smoking
cessation medication prescription 
3705 0
Smoking cessation medication prescription occurred
before 1 September 2006
355,547 0
Varenicline and NRT were issued on the same day 6986 193
Smoking cessation medication was not prescribed by a GP 118,316 11,840
Smoking cessation medication prescription had < 1 year
of historical follow-up data before prescription 
40,487 342
Bupropion prescriptions 17,058 274
Smoking cessation medication prescription that had a prior
smoking cessation medication issued within 18 months 
979,056 25,057
The patient had previously received an eligible smoking
cessation prescription 
51,246 0
Prescribing GP had seen < 10 patients 17,239 17,239
Patient had < 180 days of follow-up after
first prescription
11,998 11,998
Total excluded, n 1,655,844 66,943
Excluded from mortality and morbidity analysis 
Records Patients
Patient’s practice was not linked to Office for National
Statistics or Hospital Episode Statistics data sets  
93,418 93,418
Assessed for eligibility
Included in effectiveness 
analysis
Varenicline
(n = 70,610)
NRT
(n = 149,526)
Included in mortality and
morbidity analysis 
NRT
(n = 84,976)
Varenicline
(n = 41,742)
• Records, n = 220,136
• Patients, n = 220,136
• Records, n = 126,718
• Patients, n = 126,718
• Records, n = 1,875,980
• Patients, n = 287,079
FIGURE 2 Flow chart of inclusion and exclusion from the study.16,17
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Intervention
The intervention was the first prescription of either smoking cessation treatment in the eligible period.
We compared the effect of prescribing varenicline with the effect of prescribing NRT. We focus on the
first recorded treatment because subsequent treatment decisions are likely to be highly non-random.
We extracted the date of the first prescription from the patients’ records.
Follow-up
Follow-up started on the date that each patient received their first prescription and ended when they
had an event, died or left the practice.
Outcomes
We assessed all outcomes at 3, 6, 9, 12, 24 and 48 months after the first prescription. We took the
date of diagnosis from the first record that indicated an outcome after the first prescription. We
excluded patients who were prevalent cases at the time of their first prescription from these analyses.
Smoking cessation
We defined smoking cessation using GP records that indicated the patients’ smoking status. Each
patient had multiple records that stated their smoking status, which can be indicated as current, former
or never smoker. GPs were incentivised to record their patients’ smoking status as part of the Quality
and Outcomes Framework.18 We defined smoking cessation as the status indicated by the most recent
record within each follow-up period. If patients had no record that indicated their smoking status but
were prescribed smoking cessation medication, we assumed that they had relapsed. We conducted
sensitivity analyses to investigate whether or not our results were affected when we assumed that all
unobserved smokers relapsed.
Mortality
We defined mortality using the linked ONS mortality data. This data set gave the date and primary
causes of death. We investigated the following secondary outcomes: mortality due to chronic lung
disease [International Statistical Classification of Diseases and Related Health Problems, Tenth Revision19
(ICD-10) codes = J40–44], lung cancer (ICD-10 code = C34), coronary heart disease (ICD-10 codes =
I21–25), pneumonia (ICD-10 codes = J12–18), cerebrovascular disease (ICD-10 codes = I60–69),
diabetes (ICD-10 codes = E10–14) and external causes (ICD-10 codes = V01–Y98).
Hospitalisation
We identified episodes of hospitalisation using the linked Hospital Episode Statistics data set, which
provides the date and cause of hospitalisation for all linked patients. We investigated both all-cause
hospitalisation and cause-specific hospitalisation using the codes described above for mortality.
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Primary care diagnosis and attendance
Primary care diagnoses of myocardial infarction, chronic obstructive pulmonary disease (COPD) and
depression, and prescriptions of hypnotics and anxiolytics were identified using validated code lists.
The frequency that each patient attended primary care was identified from their records.
Weight
The patients’ weight in the months following their initial prescription was identified using their
electronic medical records.
Potential confounders
The potential confounders included the following variables measured at baseline: age; body mass
index (BMI); alcohol drug misuse, defined using Read codes; SEP measured by the Index of Multiple
Deprivation (IMD); an indicator for having more than five primary care consultations in the year
before first prescription; indicators for year of prescription; any previous prescriptions of hypnotics;
any previous prescriptions of antipsychotics; any previous prescriptions of antidepressants; diagnoses
of self-harm; diagnoses of myocardial infarction; diagnoses of COPD; any psychiatric disease; or any
serious comorbidity (a non-zero Charlson Comorbidity Index). We accounted for missing data by using
imputation by chained equations, because some patients were missing BMI and SEP data.
Statistical methods
We estimated the effects of varenicline and NRT using three statistical methods: multivariable-adjusted
logistic regression, propensity score matched regression and instrumental variable regression. We did
not use Cox survival models because the proportional hazards assumption did not hold. Our basic
adjusted models adjust for sex, year of first prescription and age. Our fully adjusted results also adjust
for all confounders described above. We used propensity score and the covariates described above
to match patients who were treated with varenicline to other similar patients prescribed NRT using
one-to-one matching with no calliper. There was a complete overlap in the propensity scores between
smokers who were prescribed varenicline and who were prescribed NRT. The propensity score
depends on similar assumptions to multivariable-adjusted regression (conditional exchangeability).
Both approaches could suffer from residual confounding. We addressed residual confounding using
instrumental variable analysis.
Instrumental variable analysis requires a variable, the ‘instrument’ that is defined by the following three
assumptions: (1) the instrument associates with the exposure of interest, (2) the instrument does not
associate with unobserved confounding factors and (3) the instrument affects the outcome only via the
exposure.20 A widely used instrument in pharmacoepidemiology is physicians’ prescribing preferences for
different medications.21 We cannot directly measure GPs’ preferences, but we can use their prescriptions
to previous patients as a proxy for their preferences. We investigated whether or not the instrumental
variable assumptions held by (1) testing the association of their prior prescriptions to their previous
seven patients with their subsequent prescriptions and (2) investigating the association with potential
confounders. We estimated the effects of varenicline and NRT using additive structural models for binary
outcomes and two-stage least squares for continuous outcomes.
All standard errors account for the clustering of patients at the practice level. We published all analytic
scripts used to generate the data to GitHub.22,23
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Changes to the protocol
Survival analysis
Our original protocol proposed to use survival analysis to estimate hazard ratios of events. However,
there was evidence that the proportional hazards assumption was violated; therefore, we dichotomised
the outcomes instead.
Definition of mortality and hospitalisation outcomes
Peer reviewers of Davies et al.16 noted that our original definition of our cause-specific outcomes was
relatively general (diseases of the respiratory system, ICD-10 = J00–99 and cardiovascular disease,
ICD-10 = I00–52) and recommended reporting more specific causes of death. As a result, we amended
our protocol to include the following eight outcomes defined by ICD-10 code: (1) chronic lung disease
(ICD-10 = J40–44), (2) lung cancer (ICD-10 = C34), (3) coronary heart disease (ICD-10 = I21–25),
(4) pneumonia (ICD-10 = J12–18), (5) cerebrovascular disease (ICD-10 = I60–69), (6) diabetes
(ICD-10 E10–14) and (7) external causes (ICD-10 V01–Y98). We used the same set of codes to
define cause-specific mortality and hospital admission.
Cancer registry outcomes
Our protocol originally intended to use data from the National Cancer Registry. However,
unfortunately, the CPRD was not able to provide access to this data set. To overcome this, we revised
our protocol to use data from primary and secondary care to identify cancer cases. These alternative
sources of information are reliable indicators of cancer diagnosis date and type.24
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Chapter 3 The effectiveness of varenicline
for smoking cessation
Parts of this text have been reproduced from Taylor et al.
17 © The Author 2017. Published by Oxford
University Press on behalf of the International Epidemiological Association. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
In this chapter, we estimate the effects of prescribing varenicline or NRT on patients’ likelihood of
smoking cessation using multivariable-adjusted, propensity score and instrumental variable regression.
Varenicline has been demonstrated to be efficacious in RCTs and network meta-analysis of RCTs.
However, these trials had < 1 year of follow-up and may not have been representative of the population
seen in primary care.
Population characteristics
Between 1 September 2006 and the end of follow-up, 1,875,980 smoking cessation prescriptions were
issued to 287,079 patients. Of these, 220,136 patients met our eligibility criteria (see Figure 2 for a
flow chart of exclusion and inclusion of prescriptions and patients into the study). Patients who were
prescribed NRT received patches, gum, oral or nasal spray, inhaler, lozenges or microtabs, and 23%
received more than one type of NRT at their first prescription. The proportion of current smokers
who were prescribed NRT or varenicline in primary care has fallen between 2007 and 2015 (Figure 3).
Nationally, the number of NRT prescriptions issued fell by 65% from 110,608 in February 2013 to
38,303 in January 2018. Prescriptions of varenicline fell by 59% from 71,551 in February 2013 to
29,645 in January 2018.25
Table 1 shows the baseline characteristics of the patients who were prescribed varenicline and NRT.
Patients who were prescribed varenicline were healthier in almost every way. They were younger,
visited their GP less frequently, had fewer comorbidities, were less likely to have misused alcohol or
drugs, were less likely to have a diagnosis of bipolar disorder, depression, a neurotic disorder, self-harm,
a rare mental disorder, or were less likely to be prescribed antidepressants, antipsychotics, hypnotics/
anxiolytics or other psychotropic medications. There were few differences by BMI or length of prior
registration.
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FIGURE 3 The per cent of smokers prescribed NRT or varenicline between 2007 and 2015 in the CPRD.
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Differences in smoking cessation rates by treatment prescribed
Patients prescribed varenicline were more likely to be recorded as a former smoker at all follow-up
periods (Figure 4). Three months after the first prescription, 18.8% and 14.1% of patients prescribed
varenicline and NRT, respectively, were recorded as a former smoker. These proportions increased to
32.3% and 28.4%, respectively, by 4 years after the first prescription. Figure 5 and Table 2 illustrate the
relative difference in quit rates between the two treatments over time. Patients prescribed varenicline
were 47% [95% confidence interval (CI) 42% to 52%] more likely to quit after 3 months than patients
prescribed NRT. The relative difference in quit rates fell over time; patients prescribed varenicline were
23% (95% CI 21% to 26%) more likely to have quit after 4 years than patients prescribed NRT. These
differences slightly attenuated, but remained detectable, after multiple imputation and adjustment for
a full range of confounders.
TABLE 1 Baseline characteristics of the sampled patients by prescription received
Characteristic
NRT
(N= 149,526)
Varenicline
(N= 70,610)
Whole sample
(N= 220,136)
Age at time of their first prescription (years),a mean (SD) 46.4 (15.4) 44.5 (13.2) 45.8 (14.9)
Sex (female), % (n) 53.7 (80,348) 50.2 (35,466) 52.6 (115,814)
IMD score, median 12 12 12
Number of GP visits 1 year prior to first prescription,a
mean (SD)
7.9 (7.4) 6.3 (6.1) 7.4 (7.0)
BMI (kg/m2),a,b mean (SD) 26.4 (6.4) 26.5 (5.9) 26.4 (6.1)
Year of first prescription 2009 2010 2009
Days of history,a mean (SD) 3158.7 (1892.1) 3283.9 (1976.6) 3198.9 (1920.5)
Comorbidity ever (Charlson Comorbidity Index), % (n) 37.6 (56,274) 31.9 (22,523) 35.8 (78,797)
Alcohol misuse ever, % (n) 8.3 (12,422) 6.0 (4199) 7.6 (16,621)
Drug misuse ever, % (n) 3.1 (4595) 1.9 (1357) 2.7 (5952)
Bipolar disorder ever, % (n) 1.0 (1464) < 1.0 (160) < 1.0 (1624)
Depression ever, % (n) 35.0 (52,233) 29.2 (20,615) 33.1 (72,848)
Neurotic disorder ever, % (n) 24.7 (36,921) 20.1 (14,189) 23.2 (51,110)
Self-harm ever, % (n) 10.6 (15,903) 8.7 (6169) 10.0 (22,072)
Other rare mental disorder ever, % (n) 6.9 (10,343) 4.0 (2832) 6.0 (13,175)
Antidepressant prescription ever, % (n) 50.1 (74,921) 43.1 (30,435) 47.9 (105,356)
Antipsychotic prescription ever, % (n) 20.0 (29,873) 14.8 (10,459) 18.3 (40,332)
Hypnotics/anxiolytics prescription ever, % (n) 21.1 (31,513) 17.6 (12,415) 20.0 (43,928)
Other psychotropic medication, % (n) < 1.0 (473) < 1.0 (120) < 1.0 (593)
SD, standard deviation.
a Days of history are the number of days from current registration date to date of first prescription.
b Missing data: BMI data were missing for 14.2% (n= 31,169) of patients and IMD data were missing for 43.3%
(n = 95,355) of patients. Missing BMI and IMD values were imputed using multiple imputation.26
Parts of this table are reproduced from Taylor et al.17 © The Author 2017. Published by Oxford University Press on
behalf of the International Epidemiological Association. This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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In almost every way we could measure, patients who were prescribed varenicline were different from
those who were prescribed NRT. As a result, we were concerned that our multivariable results might
suffer from residual confounding. Therefore, we estimated the effects of the medications using propensity
score and instrumental variable methods. The patients’ characteristics were well balanced across the
propensity score (see Report Supplementary Material 1, Figures S1 and S2). The covariate balance tests
presented in Report Supplementary Material 1, Figure S3, suggest that the measured covariates were
more balanced across the instrument than across the actual prescription. The effects of prescribing
varenicline estimated using the propensity score and instrumental variable analysis were consistent
with the multivariable-adjusted regression above (see Report Supplementary Material 1, Tables S1 and S2).
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FIGURE 4 The proportion of patients who quit, by medication prescribed, at 3, 6 and 9 months and 1, 2 and 4 years
after exposure (n = 220,136). Reproduced from Taylor et al.17 © The Author 2017. Published by Oxford University Press
on behalf of the International Epidemiological Association. This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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FIGURE 5 Patients prescribed varenicline were more likely to be non-smokers 3, 6 and 9 months and 1, 2 and 4 years
after their first prescription than those prescribed NRT. Fully multivariable-adjusted logistic regression model using
multiply imputed data: odds ratios and 95% CIs presented. The difference in smoking cessation rates peaks at 6 months
and declines over the following 3.5 years (n = 220,136). Reproduced from Taylor et al.17 © The Author 2017. Published by
Oxford University Press on behalf of the International Epidemiological Association. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Heterogeneity in the effect of varenicline by socioeconomic position
Patients from more deprived areas were 9% (95% CI 8% to 10%) less likely to be prescribed varenicline
after controlling for age and sex. Patients from areas in the least deprived quintile were slightly more
likely to have quit between 3 and 12 months after their first prescription. However, these differences
could be attributable to chance (p > 0.05). The longer-term (after 2 and 4 years) differences in relative
quit rates by treatment were similar in areas of high and low deprivation (Figure 6). Therefore, there
was little evidence that the effects of varenicline and NRT differed across socioeconomic groups. There
was insufficient statistical power to detect treatment effect heterogeneity using instrumental variable
analysis (see Report Supplementary Material 1, Tables S3 and S4). However, instrumental variable point
estimates suggested that varenicline increased the likelihood of smoking cessation at all follow-up periods.
TABLE 2 Multivariable logistic regression models: partial and fully adjusted odds ratios and 95% CIs for the association
between varenicline and NRT and smoking cessation at 3, 6 and 9 months and 1, 2 and 4 years after exposure
(n = 220,136)a
Model
Odds ratio (95% CI)
3 months 6 months 9 months 1 year 2 years 4 years
Partial adjustedb 1.47
(1.42 to 1.52)
1.50
(1.46 to 1.55)
1.44
(1.4 to 1.48)
1.38
(1.35 to 1.42)
1.30
(1.27 to 1.33)
1.23
(1.21 to 1.26)
Fully adjustedc 1.42
(1.38 to 1.47)
1.46
(1.42 to 1.50)
1.40
(1.36 to 1.44)
1.34
(1.31 to 1.38)
1.26
(1.23 to 1.29)
1.19
(1.16 to 1.21)
a Missing BMI and IMD values were imputed using multiple imputation.27
b Partial adjusted models were adjusted for: age, sex and year of prescription.
c Fully adjusted models were adjusted for age, sex, days in history, IMD, number of GP visits 1 year prior to their
first prescription, BMI, year of first prescription, history of major physical morbidity (Charlson Comorbidity Index),
alcohol misuse, drug misuse, bipolar disorder, depression, neurotic disorder, self-harm, other mental disorder,
antidepressant prescription ever, antipsychotic prescription ever, hypnotics/anxiolytics prescription ever, and other
psychotropic medication.
Parts of this table are reproduced from Taylor et al.17 © The Author 2017. Published by Oxford University Press on
behalf of the International Epidemiological Association. This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
1.6
1.5
1.4
1.3
1.2
1.1
O
d
d
s 
ra
ti
o
3 6 9 12 24 48
Effect in areas of
low deprivation
Effect in areas of
high deprivation
Months since first prescription
FIGURE 6 The effectiveness of varenicline stratified by SEP. Partially adjusted odds ratios and 95% CIs for the association
of prescription of varenicline vs. NRT and smoking cessation at 3, 6 and 9 months and 1, 2 and 4 years after exposure,
by the level of deprivation as measured by the IMD. IMD is an increasing measure of neighbourhood disadvantage.
Reproduced from Taylor et al.17 © The Author 2017. Published by Oxford University Press on behalf of the International
Epidemiological Association. This is an Open Access article distributed under the terms of the Creative Commons
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Sensitivity analyses
Missing data
Patients prescribed varenicline and NRT had similar numbers of missing data. After 2 years, 20.3%
of patients had no new smoking status records (see Report Supplementary Material 1, Table S5). The
patients who were missing smoking status records were more likely to be younger and male, were
less likely to visit the GP and had fewer comorbidities (see Report Supplementary Material 1, Table S6).
We investigated whether or not the missing smoking status records affected our results using multiple
imputation. The multiply imputed results were similar to our main results, which assumed that patients
with no smoking status records in the follow-up period were continuing smokers (see Report
Supplementary Material 1, Table S7).28
Varenicline versus nicotine replacement monotherapy versus multitherapy
Patients who were prescribed varenicline were more likely to have ceased smoking after 2 years
than those who were prescribed any NRT [odds ratio (OR) 1.30, 95% CI 1.27 to 1.33]. Patients who
were prescribed varenicline were more likely to have ceased smoking after 2 years than patients who
were prescribed NRT monotherapy defined by route of administration (OR 1.32, 95% CI 1.29 to 1.36).
Patients who were prescribed varenicline were more likely to have ceased smoking after 2 years
than patients who were prescribed NRT multitherapy (OR 1.23, 95% CI 1.19 to 1.27). Patients who
were prescribed NRT multitherapy were more likely to have ceased smoking after 2 years than those
prescribed NRT monotherapy (OR 1.08, 95% CI 1.05 to 1.12). After adjustment for the same set of
covariates as we included in the primary analysis, the OR of cessation at 2 years comparing varenicline
with NRT multitherapy was 1.22 (95% CI 1.17 to 1.28). The fully adjusted OR for cessation at 2 years
comparing varenicline with NRT monotherapy was 1.23 (95% CI 1.19 to 1.28). After adjustment, there
was little evidence of differences in quit rates between those prescribed NRT monotherapy and NRT
multitherapy (OR 1.01, 95% CI 0.97 to 1.05). These results suggest that patients who were prescribed
varenicline were more likely to be non-smokers after 2 years than patients who were prescribed either
NRT monotherapy or NRT multitherapy.
Treatment compliance
On average, patients who were prescribed varenicline were issued 2.8 [standard deviation (SD) 1.6]
prescriptions for varenicline in the 3 months following their first eligible prescription, and received
an average of 107.5 (SD 120.7) tablets; 49.7% (35,076/70,610) of these patients received a full course
of varenicline (i.e. ≥ 12 weeks) (see British National Formulary, chapter 4.10.214). Patients who were initially
prescribed NRTwere issued 2.5 (SD 2.2) prescriptions for NRT on average during the 3 months after
their first eligible prescription. Patients who were issued a single varenicline prescription only were less
likely to cease smoking after 2 years than those who were prescribed any NRT (OR 0.59, 95% CI 0.57
to 0.62). Patients who were prescribed at least two varenicline prescriptions were more likely to cease
smoking after 2 years than those prescribed any NRT (OR 1.63, 95% CI 1.59 to 1.67). Patients prescribed
two or more varenicline prescriptions in the 2 months following their first prescription were more
likely to cease smoking than those who were issued a single varenicline prescription (OR 2.80, 95% CI
2.67 to 2.92). After adjustment for the same set of covariates as we included in the primary analysis,
the difference in cessation between patients issued a single varenicline prescription and those issued
NRT increased (OR 0.55, 95% CI 0.51 to 0.58). The difference in cessation at 2 years between patients
prescribed two or more varenicline prescriptions and any NRT attenuated (OR 1.51, 95% CI 1.46 to
1.57). The adjustment did not meaningfully alter the difference between patients prescribed two or more
varenicline prescriptions and those prescribed a single varenicline prescription (OR 2.79, 95% CI 2.61 to
2.97). These results suggest that patients who were prescribed two or more varenicline prescriptions,
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who have a longer duration of treatment, were less likely to be smokers after 2 years than those
prescribed either NRT monotherapy or NRT multitherapy.
Multiple quit attempts
Patients who were prescribed varenicline were more likely to quit smoking than patients who were
prescribed NRTwho had previously had any smoking cessation prescriptions (OR 1.27, 95% CI 1.22 to
1.31). After adjustment for the same set of covariates as included in the primary analysis, the association
in patients previously prescribed smoking cessation prescription remained similar (OR 1.27, 95% CI 1.22
to 1.33). Patients who had never previously been prescribed smoking cessation treatment who were
prescribed varenicline were more likely to cease smoking than those who were prescribed NRT (OR 1.32,
95% CI 1.29 to 1.36). This association attenuated after adjustment for the covariates included in the
primary analysis (OR 1.23 95% CI 1.19 to 1.29). Patients who had previously received a smoking cessation
prescription were less likely to quit (OR 0.90, 95% CI 0.88 to 0.92) than those who had never received a
smoking cessation prescription. This difference attenuated after adjustment (OR 0.93, 95% CI 0.91 to
0.96). These results suggest that patients prescribed varenicline are more likely to have ceased smoking
after 2 years, irrespective of whether or not they had previously been prescribed smoking cessation
therapy. Patients who had previously received smoking cessation therapies were less likely to quit.
Comparison with other studies
Figure 7 compares our results with the previously published results from RCTs. Our estimates of the
effectiveness of varenicline compared with NRT at 6 months were similar to, and considerably more
precise than, the results estimated via the large RCT reported by Anthenelli et al.10 and a network
meta-analysis conducted by Cahill et al.7 Combined, the studies suggested that, on average, patients
prescribed varenicline were 44% (95% CI 33% to 55%) more likely to quit smoking after 6 months.
Study
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Anthenelli et al.10
Aubin et al.30
Taylor et al.17
Observational study
Overall (I2 = 27.1%; p = 0.241)
1.57 (1.29 to 1.91)
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FIGURE 7 Random-effects meta-analysis comparing effect estimates (OR and 95% CI) from existing studies examining
the effect of varenicline vs. NRT for smoking cessation at 6- to 12-month follow-up. Reproduced from Taylor et al.17
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Chapter 4 The effects of prescribing
varenicline on longer-term health outcomes
Parts of this text have been reproduced from Davies et al.
16 © 2018 The Authors. Addiction
published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an
open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
Although randomised trials are the gold standard for demonstrating efficacy, they are underpowered to
detect the effect of treatments on rare secondary outcomes and have a limited follow-up. For smoking
cessation treatments, follow-up is generally ≤ 1 year. In this chapter, we investigate the effect of
varenicline on health outcomes between 3 and 48 months after the first prescription. In the results
presented below, we focus on the instrumental variable analyses because the specification tests
suggested that the multivariable-adjusted and propensity score regression results may suffer from
residual confounding. We present the results for the propensity score analysis in Report Supplementary
Material 1, Tables S9–S11.
Population characteristics
Of the 287,079 patients who were prescribed smoking cessation treatments during the study period,
126,718 patients met inclusion criteria for assessing the health outcomes. Of these patients, most
(84,976, 67.1%) were prescribed NRT and the remainder (41,742, 32.9%) were prescribed varenicline.
Most (73%) of the patients who were prescribed varenicline were issued an additional prescription of
varenicline in the 3 months following their first prescription. However, only 20% of patients were issued
≥ 151 tablets within the 3-month treatment window. This is the minimum number of tablets patients
needed to adhere to a full course of treatment. As with the effectiveness analysis presented in Chapter 3,
patients in this restricted sample who were prescribed varenicline, and had linked Hospital Episode
Statistics and ONS mortality data, were healthier in almost every way that we could measure (Table 3).
TABLE 3 Baseline characteristics of patients prescribed varenicline or NRT
Characteristic NRT (N= 84,976) Varenicline (N= 41,742)
Male, n (%) 39,285 (46.2) 20,928 (50.1)
Median age (years) (SD) 46 (24) 44 (19)
BMI (kg/m2), mean (SD) 25.5 (7.1) 25.7 (6.6)
Misuses alcohol, n (%) 6199 (7.3) 2086 (5.0)
Misuses drugs, n (%) 2484 (2.9) 747 (1.8)
Least deprived fifth of patients, n (%) 11,209 (13.2) 6427 (15.4)
Most deprived fifth of patients, n (%) 20,896 (24.6) 9177 (22.0)
Median number of primary care visits in prior year (SD) 6 (8) 5 (6)
Prescribed before 2009, n (%) 38,568 (45.4) 10,422 (25.0)
continued
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Specification tests of the instrumental variable assumptions
The physicians’ previous prescriptions were strongly associated with their prescriptions to their
subsequent patients. A doctor who issued varenicline to their previous patient was 24.5% (95% CI
23.3% to 25.9%) more likely to prescribe varenicline to their subsequent patients. The instrument
was the number of varenicline prescriptions issued to the physicians’ previous seven patients who
were receiving smoking cessation treatment. Hence, the physicians’ prescribing behaviours explain
a substantial proportion of the variation in treatment rates. The partial F-statistic, a measure of
instrument strength, ranged from 4045 to 7775.31 A value of the partial F-statistic ≥ 10 suggests
that the analysis is unlikely to suffer from weak instrument bias.32 This value of the F-statistic does
not guarantee that the estimates will be unbiased, or will be sufficiently powered to detect effect
sizes of interest. However, it does mean that the coverage of the estimates (CIs) should be correct.
Values of the F-statistic < 10 can result in overly precise CIs and over-rejection of the null hypothesis.
This problem is a particular concern in analyses with more than one instrument. This statistic indicates
that the instrument was very strong. Furthermore, the potential confounders were more balanced
across the instrument than across the patients’ prescriptions (Figure 8 and also see Report Supplementary
Material 1, Table S8). These results mean that even after taking account of the strength of the physicians’
preferences (the instrument), the bias for the instrumental variable analysis (attributable to all of the
observed potential confounders except BMI, the number of prior GP visits and deprivation) was likely
to be lower than for the patients’ prescriptions. The estimated instrumental variable bias terms for
BMI, number of GP visits and deprivation were similar to the linear regression bias terms.
TABLE 3 Baseline characteristics of patients prescribed varenicline or NRT (continued )
Characteristic NRT (N= 84,976) Varenicline (N= 41,742)
Previous prescription of, n (%)
Hypnotics/anxiolytic 17,419 (20.5) 7114 (17.0)
Antipsychotic 16,918 (19.9) 5975 (14.3)
Antidepressant 42,450 (50.0) 17,895 (42.9)
Statins 16,534 (19.5) 6217 (14.9)
Antihypertensive 17,608 (20.7) 6974 (16.7)
Diabetic medication 7798 (9.2) 2710 (6.5)
Previous diagnosis of, n (%)
Self-harm 8846 (10.4) 3614 (8.7)
Myocardial infarction 2624 (3.1) 708 (1.7)
COPD 6837 (8.0) 2516 (6.0)
Chronic disease (Charlson Comorbidity Index) 32,517 (38.3) 13,277 (31.8)
Any psychiatric disease 41,275 (48.6) 17,005 (40.7)
Follow-up time (years), mean (SD) 4.56 (2.07) 3.72 (1.84)
SD, standard deviation.
Reproduced from Davies et al.16 © 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society
for the Study of Addiction. This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
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The effects of varenicline on mortality and morbidity after 2 years
Patients prescribed varenicline had slightly higher rates of all-cause mortality than those who were
prescribed NRT (risk difference per 100 patients treated = 0.67, 95% CI –0.11 to 1.46) (Figure 9). From
the instrumental variable analyses, there were few detectable differences in cause-specific mortality,
all-cause or cause-specific hospitalisation, or primary care diagnoses of myocardial infarction or COPD
(see Figure 9). Our results suggest that positive or negative effects > 2.5 per 100 patients treated
are unlikely for all-cause hospitalisation. Varenicline is unlikely to cause positive or negative effects
> 1 per 100 patients on the other outcomes, including a lung cancer diagnosis.
Consistent with the broader literature, the multivariable-adjusted results suggested that after 2 years,
patients who were prescribed varenicline had substantially lower mortality and morbidity than patients
who were prescribed NRT (Figure 10). Patients who were prescribed varenicline had lower rates of
all-cause and cause-specific mortality, except lung cancer (Figure 11). After fully adjusting for all the
baseline confounders listed in Table 3, the estimates modestly attenuated towards the null; however,
substantial differences remained. The multivariable-adjusted estimates systematically differed from
the instrumental variable estimates of the effect of varenicline after 2 years on all-cause mortality and
hospital admission (pHausman = 4.14 × 10–9 and 6.35 × 10–8 respectively). The Hausman test is a test for
the difference between the ordinary least squares and instrumental variable estimates. There were
systematic differences in estimated effects on cause-specific mortality: chronic lung disease, coronary
heart disease, pneumonia and diabetes (pHausman = 0.0006, = 0.005, = 0.001 and = 0.04 respectively).
Male sex
Misuses alcohol
Misuses drugs
Most deprived quintile IMD
Least deprived quintile IMD
Hypnotics
Antipsychotics
Antidepressants
Statins
Antihypertensive medications
Diabetic medications
Self-harm
Myocardial infarction
COPD
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Any psychiatric diagnosis
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FIGURE 8 The bias terms for linear and instrumental variable regression. These plots indicate the bias caused by omitting
a single observed covariate from a multivariable-adjusted or instrumental variable regression analysis. This analysis treats
the omitted covariate as an ‘outcome’ and the exposure or instrumental variable (prior prescription) as the dependent
variable. Relative linear regression and instrumental variable bias component terms are indicated by squares (▪) and
triangles (▲) respectively. 95% CIs are plotted. The patients’ actual prescriptions more strongly associated with the
measured covariates than the proposed instrument, even after taking into account the instrument strength. This statistic
suggests that the instrumental variable estimates are likely to be less biased than the linear regression estimates. CIs
allow for clustering between physicians. We adjusted each bias term except sex for year, sex and age and no other
covariates. The instrumental variable was defined using seven prior prescriptions. Reproduced from Davies et al.16 © 2018
The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an
Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting
changes to the original text.
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The instrumental variable results were inconsistent with the reduction in risk of hospitalisation for
coronary heart disease estimated via multivariable adjustment (pHausman = 0.006). The effects of varenicline
on other cause-specific hospitalisation, weight and the number of GP visits were similar for both
multivariable-adjusted regression and instrumental variable regression.
The effects of varenicline versus nicotine replacement therapy over time
Figure 10 illustrates the effects of prescribing varenicline versus NRT on rates of all-cause and cause-
specific mortality over time. The navy line indicates the effects as estimated via instrumental variables
and the solid light blue line indicates the minimally adjusted multivariable-adjusted regression. The
dashed light blue line indicates the fully adjusted multivariable-adjusted regression estimates. The
instrumental variable estimates provide little evidence that varenicline affects mortality at any follow-up
period. The partially adjusted multivariable estimates suggest that all-cause and cause-specific mortality
risks generally drop linearly after the first prescription. The exception to this is lung cancer mortality,
which drops more quickly in months 3–6 than months 6–48. Adjustment for the full range of covariates
Outcome
Risk difference per
100 patients treated
(95% CI)
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Chronic lung disease (J40–44)
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Lung cancer (C34)
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Anxiety
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Chronic obstructive pulmonary disease
Myocardial infarction
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–0.12 (–0.40 to 0.15)
–0.18 (–0.52 to 0.16)
–0.01 (–0.20 to 0.19)
–0.01 (–0.12 to 0.11)
–0.00 (–0.27 to 0.26)
0.19 (–0.14 to 0.51)
0.15 (–0.29 to 0.59)
0.33 (–0.13 to 0.80)
0.21 (–0.37 to 0.79)
0.27 (–2.05 to 2.59)
0.09 (–0.04 to 0.22)
0.02 (–0.13 to 0.17)
0.14 (–0.09 to 0.37)
0.18 (–0.08 to 0.45)
0.20 (–0.08 to 0.48)
0.67 (–0.11 to 1.46)
1.48 (–0.57 to 3.53)
Favours varenicline Favours NRT
FIGURE 9 The effects of prescribing varenicline vs. NRT on mortality and morbidity in the 2 years following the first
prescription. The estimates are calculated from instrumental variable regression. CIs allow for clustering between physicians.
Instrumental variable results use seven prior prescriptions and adjust for the year of first prescription, sex and age.
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FIGURE 10 The effect of prescribing varenicline on (a) all-cause, (b) chronic lung disease-related (ICD-10 J40–44),
(c) lung cancer (ICD-10 C34), (d) coronary heart disease (ICD-10 I21–25), (e) pneumonia-related (ICD-10 J12–18) and
(f) cerebrovascular disease-related (ICD-10 I60–69) mortality in the 4 years following first prescription as indicated via ONS
mortality records. Linear regression is indicated by squares (▪), the solid line adjusts for basic confounders, the dashed
line adjusts for all confounders listed in Table 3, and the instrumental variable results are indicated by triangles (▲).
95% CIs are indicated. CIs allow for clustering between physicians. The multivariable-adjusted results adjust for all the
covariates listed in Table 1. Instrumental variable results use seven prior prescriptions. Reproduced from Davies et al.16
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FIGURE 10 The effect of prescribing varenicline on (a) all-cause, (b) chronic lung disease-related (ICD-10 J40–44),
(c) lung cancer (ICD-10 C34), (d) coronary heart disease (ICD-10 I21–25), (e) pneumonia-related (ICD-10 J12–18) and
(f) cerebrovascular disease-related (ICD-10 I60–69) mortality in the 4 years following first prescription as indicated via ONS
mortality records. Linear regression is indicated by squares (▪), the solid line adjusts for basic confounders, the dashed
line adjusts for all confounders listed in Table 3, and the instrumental variable results are indicated by triangles (▲).
95% CIs are indicated. CIs allow for clustering between physicians. The multivariable-adjusted results adjust for all the
covariates listed in Table 1. Instrumental variable results use seven prior prescriptions. Reproduced from Davies et al.16
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FIGURE 11 The effect of prescribing varenicline on (a) all-cause, (b) chronic lung disease-related (ICD-10 J40–44),
(c) lung cancer (ICD-10 C34), (d) coronary heart disease (ICD-10 I21–25), (e) pneumonia-related (ICD-10 J12–18) and
(f) cerebrovascular disease-related (ICD-10 I60–69) hospital inpatient admission in the 4 years following first prescription as
indicated via ONS death records. Linear regression is indicated by squares (▪), the solid line adjusts for basic confounders,
the dashed line adjusts for all confounders listed in Table 3 and the instrumental variable results are indicated by triangles
(▲). 95% CIs are indicated. CIs allow for clustering between physicians. The fully multivariable-adjusted results adjust
for all the covariates listed in Table 1. Instrumental variable results use seven prior prescriptions. Reproduced from Davies
et al.16 © 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
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FIGURE 11 The effect of prescribing varenicline on (a) all-cause, (b) chronic lung disease-related (ICD-10 J40–44),
(c) lung cancer (ICD-10 C34), (d) coronary heart disease (ICD-10 I21–25), (e) pneumonia-related (ICD-10 J12–18) and
(f) cerebrovascular disease-related (ICD-10 I60–69) hospital inpatient admission in the 4 years following first prescription as
indicated via ONS death records. Linear regression is indicated by squares (▪), the solid line adjusts for basic confounders,
the dashed line adjusts for all confounders listed in Table 3 and the instrumental variable results are indicated by triangles
(▲). 95% CIs are indicated. CIs allow for clustering between physicians. The fully multivariable-adjusted results adjust
for all the covariates listed in Table 1. Instrumental variable results use seven prior prescriptions. Reproduced from Davies
et al.16 © 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
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reported in Table 1 resulted in little change in the estimates. One explanation of the difference between
the instrumental variable and multivariable-adjusted results is that the latter suffer from residual
confounding.
Figure 11 illustrates the effects of prescribing varenicline over 4 years on all-cause and cause-specific
hospitalisation. The instrumental variable estimates suggest a modest reduction in all-cause admissions
in the 3–9 months following the first prescription. There is little difference in rates of hospitalisation
between months 12 and 24, and an imprecise positive effect at 48 months. The instrumental variable
estimates of the effect of varenicline are too imprecise to distinguish them from the null hypothesis
or the multivariable-adjusted estimates. The partially adjusted multivariable estimates of the effect on
all-cause hospitalisation suggest a substantial protective effect that peaks 12 months after the first
prescription, before modestly attenuating by 48 months. The cause-specific estimates for chronic lung
disease, pneumonia and cerebrovascular disease suggest a protective effect. There was little evidence
of a difference in the rates of admission for lung cancer or (after full adjustment) for coronary heart
disease. These differences attenuated towards the null after adjustment but remained detectable.
The instrumental variable estimates suggest that prescribing varenicline caused an increase in weight,
on average 1.14 kg (95% CI 0.09 to 2.20 kg) after 2 years; this effect was detectable across the entire
follow-up period (Figure 12). The partially multivariable-adjusted results suggested a similar increase in
weight across the entire follow-up period. The fully adjusted results were mildly attenuated towards
the null. There were little differences between the instrumental variable and multivariable-adjusted
estimates (pHausman for all follow-up periods > 0.01). The instrumental variable estimates suggest that
prescribing varenicline caused a 19.16% (95% CI 11.17% to 27.15%) reduction in the number of
primary care attendances. These estimates were consistent with the partially multivariable-adjusted
estimates, but these effects largely attenuated after adjusting for all the baseline covariates listed
in Table 3.
Figure 13 illustrates the effects of varenicline on diabetes-related mortality, diabetes-related hospital
admission, myocardial infarction and COPD. For diabetes-related mortality, the instrumental variable
analysis provides little evidence of an effect in the year after the first prescription, but shows a rapid
increase in risk by 24 and 48 months. The partially and fully adjusted multivariable-adjusted regression
results suggest that prescribing varenicline reduces the risk of diabetes-related mortality. There was
little evidence from either the instrumental variable or the multivariable-adjusted regression that
prescribing varenicline affected likelihood of diabetes-related hospital admission. The instrumental
variable point estimates suggested an increased likelihood of primary care diagnosis of myocardial
infarction and COPD in months 12–48 after the first prescription for myocardial infarction. However,
these effects were imprecise and consistent with the null and the protective effects implied by the
multivariable-adjusted estimates. The instrumental variable analysis suggested that varenicline caused
an increase in the risk of a diagnosis of COPD after 48 months, but little evidence of an effect at other
follow-up periods. The multivariable-adjusted estimates implied a reduction in risk of COPD at all
follow-up periods; these differences attenuated after adjustment for baseline confounders. For primary
care diagnosis of depression, the instrumental variable analysis provides little evidence of an effect
in any period after first prescription. The fully adjusted multivariable-adjusted regression results
suggest that prescribing varenicline is associated with a lower risk of depression in the year after the
first prescription, but little evidence of differences after ≥ 2 years. For primary care prescription of
hypnotics or anxiolytics, the instrumental variable analysis provided little evidence of an effect at any
point after the first prescription. The fully adjusted multivariable-adjusted regression analysis suggests
that patients prescribed varenicline had a lower risk of being prescribed hypnotics or anxiolytics in the
2 years following the first prescription of smoking cessation therapy, but there was little difference in
risk after 4 years.
DOI: 10.3310/hta24090 Health Technology Assessment 2020 Vol. 24 No. 9
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Davies et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
23
Figure 14 compares the experimental estimates reported in the literature with our estimates from
the CPRD. We compared the estimates 1 year after the first prescription for comparability with the
trials, which had limited follow-up. Mills et al.34 conducted a network meta-analysis of data from RCTs.
We assumed an incidence rate of 0.2% to convert the risk ratios they report to the risk difference
scale. They found little evidence of a difference in risk of major cardiovascular events. However, their
estimates were relatively imprecise and consistent with the null. The CATS trial (Cardiac Assessments
Following Different Treatments of Smoking Cessation Medications in Subjects With and Without
Psychiatric Disorders)33 reported the frequency of major adverse cardiovascular outcome but was less
precise than the network meta-analysis above and again consistent with the null. Both estimates are
also consistent with our multivariable-adjusted and instrumental variable estimates. We included Mills
et al.34 in this figure because it was a large network meta-analysis on the cardiovascular risk caused by
varenicline, and we included the CATS trial in this figure because it was a large RCT published after
Mills et al.34
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FIGURE 12 Effect of prescribing varenicline on (a) weight (kg) and (b) frequency of attendance to primary care in the 4 years
following initial prescription. Linear regression is indicated by squares (▪), the solid line is adjusted for basic confounders, the
dashed line adjusts for all confounders listed in Table 3 and the instrumental variable results are indicated by triangles (▲).
95% CIs are indicated. Reproduced from Davies et al.16 © 2018 The Authors. Addiction published by John Wiley & Sons Ltd
on behalf of Society for the Study of Addiction. This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure
includes minor additions and formatting changes to the original text.
THE EFFECTS OF PRESCRIBING VARENICLINE ON LONGER-TERM HEALTH OUTCOMES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
(a)
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Months since first prescription
R
is
k 
d
if
fe
re
n
ce
 p
er
 1
0
0
 p
at
ie
n
ts 0.6
0.4
0.2
0.0
–0.2
(b)
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Months since first prescription
R
is
k 
d
if
fe
re
n
ce
 p
er
 1
0
0
 p
at
ie
n
ts 0.5
0.0
–0.5
–1.0
(c)
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Months since first prescription
R
is
k 
d
if
fe
re
n
ce
 p
er
 1
0
0
 p
at
ie
n
ts 1.0
0.5
0.0
–0.5
FIGURE 13 Effect of prescribing varenicline on diabetes-related (ICD-10 E10–14) (a) mortality and (b) inpatient admission,
(c) primary care diagnosis of myocardial infarction, (d) COPD, (e) primary care diagnosis or prescription for depression, and
(f) prescription of hypnotics or anxiolytics in the 4 years following initial prescription. Linear regression is indicated by
squares (▪), the solid line adjusts for basic confounders, the dashed line adjusts for all confounders listed in Table 1 and
the instrumental variable results are indicated by triangles (▲). 95% CIs are indicated. CIs allow for clustering between
physicians. The fully multivariable-adjusted results adjust for all the covariates listed in Table 1. Instrumental variable results
use seven prior prescriptions. Reproduced from Davies et al.16 © 2018 The Authors. Addiction published by John Wiley &
Sons Ltd on behalf of Society for the Study of Addiction. This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
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FIGURE 13 Effect of prescribing varenicline on diabetes-related (ICD-10 E10–14) (a) mortality and (b) inpatient admission,
(c) primary care diagnosis of myocardial infarction, (d) COPD, (e) primary care diagnosis or prescription for depression, and
(f) prescription of hypnotics or anxiolytics in the 4 years following initial prescription. Linear regression is indicated by
squares (▪), the solid line adjusts for basic confounders, the dashed line adjusts for all confounders listed in Table 1 and
the instrumental variable results are indicated by triangles (▲). 95% CIs are indicated. CIs allow for clustering between
physicians. The fully multivariable-adjusted results adjust for all the covariates listed in Table 1. Instrumental variable results
use seven prior prescriptions. Reproduced from Davies et al.16 © 2018 The Authors. Addiction published by John Wiley &
Sons Ltd on behalf of Society for the Study of Addiction. This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
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Study ID
Mills et al.34 network meta-analysis of RCTs
NRT vs. varenicline
Major cardiovascular adverse event
CATS trial
Major adverse cardiovascular events
Davies22 multivariable-adjusted analysis
Cardiovascular mortality (ONS ICD-10 = I21–25)
Hospitalisation due to cardiovascular disease (HES ICD-10 = I21–25)
Primary care diagnosis of myocardial infarction (Read codes)
Davies22 instrumental variable analysis
Cardiovascular mortality (ONS ICD-10 = I21–25)
Hospitalisation due to cardiovascular disease (HES ICD-10 = I21–25)
Primary care diagnosis of myocardial infarction (Read codes)
Risk difference 
(95% CI)
–0.07 (–0.18 to 0.17)
–0.15 (–0.44 to 0.14)
–0.07 (–0.12 to –0.01)
–0.10 (–0.18 to –0.02)
0.05 (–0.11 to 0.21)
0.34 (0.00 to 0.68)
0.08 (–0.13 to 0.29)
–0.09 (–0.20 to 0.03)
–0.681 0 0.681
FIGURE 14 The effect of varenicline compared with NRT estimated using RCTs and observational studies. The Mills et al.34 estimate assumes an incidence rate of 0.2% in those allocated
to NRT.34 The CATS trial estimates are taken from reported proportions of major adverse cardiovascular events in the varenicline and NRT arms of the trial. The asymmetric CIs on the
Mills et al.34 result are because we converted the risk ratios to risk differences. Adapted from Davies et al.16 © 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of
Society for the Study of Addiction. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original text.
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Chapter 5 Prescribing of smoking cessation
products in patients recently diagnosed
with cancer
There is limited evidence about the prescribing of smoking cessation products to patients recentlydiagnosed with cancer. In this chapter, we investigate the rate of smoking in patients diagnosed
with cancer, the prevalence of prescribing smoking cessation products to patients and the effectiveness
of smoking cessation in this population. In the results presented below, we focus on the conventional
analysis for two reasons. First, we found little evidence of bias in the effectiveness analysis for the full
sample using conventional methods. Second, the sample of patients recently diagnosed with cancer is
much smaller than the full sample. Therefore, the statistical power is much lower.
Population characteristics
Of the 220,136 patients prescribed smoking cessation products sampled in the effectiveness analysis
in Chapter 3, 2965 had a diagnosis of cancer in the year before their smoking cessation prescription.
A smaller proportion of patients diagnosed with cancer (20.9%) were prescribed varenicline than
non-cancer patients (32.2%). On average, patients diagnosed with cancer were older than the general
population (59 years vs. 46 years), were more likely to be male and had more comorbidities, but were
otherwise similar (Table 4).
We extracted information on the number of patients in the entire CPRD who were diagnosed with
cancer each year. We used this information to calculate the proportion of incident cancer cases who
were current smokers. The proportion of patients with incident diagnoses of cancer was steady between
9.9% and 12.1% between 2007 and 2012 (Figure 15). Since 2012, the proportion of these patients who
smoke has steadily dropped to 6.5% in 2015. In 2007, patients with a recent diagnosis of cancer were
as likely to be prescribed NRT as those without a diagnosis, whereas they were slightly less likely to
be prescribed varenicline. Prescribing of NRT fell over the period, but less quickly for those recently
diagnosed with cancer (Figure 16). Prescribing of varenicline fell after 2012 for people with and without
a recent cancer diagnosis. By 2015, patients with a cancer diagnosis were more likely to be prescribed
varenicline than those without a cancer diagnosis.
Patients who were diagnosed with lung cancer were substantially more likely to be prescribed NRT
than varenicline across the entire period; however, prescribing rates have fallen since 2010 (Figure 17).
In contrast, prescribing rates for varenicline in this sample have increased from 2.4% in 2007 to 5.6%
in 2015.
Patients recently diagnosed with cancer were more likely to be abstinent 2 years after their first
prescription than patients without a diagnosis (Figure 18). A total of 32.7% and 29.8% of those
prescribed varenicline and NRT, respectively, were abstinent 2 years after their first prescription.
However, these figures are much more imprecise than the equivalent figures for the whole sample.
They are too imprecise to test whether or not there is a difference in effectiveness in this population
compared with the whole population.
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TABLE 4 Baseline characteristics of patients with or without incident cancer by exposure group
Characteristic
Any incident cancer (N= 2965) No incident cancer (N= 217,171)
NRT
(N= 2345)
Varenicline
(N= 620) Total
NRT
(N= 147,181)
Varenicline
(N= 69,990) Total
Age (years) at time of first prescription, mean (SD) 59.6 (12.3) 56.7 (12.2) 59.02 (12.3) 46.2 (15.5) 44.4 (13.2) 45.6 (14.8)
Sex (male), n (%) 1195 (51.0) 313 (50.5) 1508 (50.9) 67,983 (46.2) 34,831 (49.8) 102,814 (47.3)
Multiple deprivation score (IMD), mediana 12 12 12 12 12 12
Number of GP visits 1 year prior to first prescription,
mean (SD)
11.8 (9.0) 11.1 (8.6) 11.7 (8.8) 7.8 (7.3) 6.2 (6.0) 7.3 (7.0)
BMI (kg/m2), mean (SD)a 25.8 (5.3) 26.2 (5.5) 25.9 (5.4) 26.5 (5.7) 26.5 (5.4) 26.5 (5.6)
Year of first prescription, median 2009 2010 2010 2009 2010 2009
Days of history, mean (SD) 3662.8 (1996.2) 3323.5 (2012.4) 3591.8 (2004) 3150.7 (1889.3) 3283.5 (1976.3) 3193.5 (1918.8)
Comorbidity ever (Charlson Comorbidity Index), n (%) 2050 (87.4) 492 (79.4) 2542 (85.7) 54,224 (36.8) 22,031 (31.5) 76,255 (35.1)
Alcohol misuse ever, n (%) 1318 (13.6) 66 (10.7) 384 (13.0) 12,678 (8.6) 4354 (6.2) 17,032 (7.8)
Drug misuse ever, n (%) 49 (2.1) 13 (2.1) 62 (2.1) 4546 (3.1) 1344 (1.9) 5890 (2.7)
Self-harm ever, n (%) 218 (9.3) 52 (8.4) 270 (9.1) 15,719 (10.7) 6128 (8.8) 21,847 (10.1)
Ever anxiety and stress-related disorders, n (%) 663 (28.3) 156 (25.2) 819 (27.6) 41,109 (27.9) 16,266 (23.2) 57,375 (26.4)
Other behavioural/neurological disorder ever, n (%) 112 (4.8) 20 (3.2) 132 (4.5) 8259 (5.6) 2751 (3.9) 11,010 (5.1)
Ever depression, n (%) 930 (39.7) 224 (36.1) 1154 (38.9) 60,347 (41.0) 24,289 (34.7) 84,636 (39.0)
Ever antidepressants, n (%) 1205 (51.4) 303 (48.9) 1508 (50.9) 73.778 (50.1) 30,152 (43.1) 103,930 (47.9)
Ever antipsychotics, n (%) 501 (21.4) 97 (15.7) 598 (20.2) 27,183 (18.5) 9255 (13.2) 36,438 (16.8)
Ever hypnotics/anxiolytics, n (%) 1116 (47.6) 267 (43.1) 1383 (46.6) 55,871 (38.0) 23,535 (33.6) 79,406 (36.6)
Ever mood stabilisers, n (%) 149 (6.4) 16 (2.6) 165 (5.6) 7089 (4.8) 1706 (2.4) 8795 (4.1)
a Missing data: BMI data were missing for 14.2% (n = 31,169) and IMD data were missing for 43.3% (n= 95,355).
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FIGURE 15 The proportion of incident cancer patients in primary care who smoke, from 2007 to 2015.
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Chapter 6 Discussion
Aims
We aimed to investigate the effect of prescribing varenicline on smoking abstinence, all-cause and
cause-specific mortality and hospitalisation, a broad range of health outcomes and whether or not the
effects of varenicline differed by SEP.
Summary of the risks and the benefits
Effectiveness
Randomised controlled trials have demonstrated that varenicline is more efficacious than NRT for
smoking cessation. Our results demonstrate that varenicline is more effective in the general population
when prescribed as part of patient usual care. Our estimates suggested that 4.76 (95% CI 2.77 to 6.74)
additional patients would be expected to quit within 2 years per 100 patients prescribed varenicline
rather than NRT. These estimates are highly consistent with results from RCTs.10 There was little
evidence of large differences in effectiveness by SEP.
Health outcomes
Patients prescribed varenicline had lower all-cause and cause-specific mortality; however, they were
healthier than those prescribed NRT in almost all ways we could measure at baseline. Therefore, the
multivariable-adjusted results are likely to suffer from a degree of residual confounding. We addressed
this using instrumental variable analysis. Our instrumental variable results found little evidence that
varenicline caused large reductions in mortality. Similarly, smokers who were prescribed varenicline
had lower rates of all-cause and most types of cause-specific hospital admission than those prescribed
NRT. However, our instrumental variable results for hospitalisation were imprecise and consistent
with the null and the multivariable-adjusted results. All analytic methods suggested that, on average,
patients prescribed varenicline gained around 1 kg in weight and attended primary care less frequently.
There was some evidence from the instrumental variable analysis that prescribing varenicline increased
the risk of diabetes-related mortality.
Public and patient involvement
Aim
To get feedback on our study from the patients and the public.
Methods
On 30 September 2015, we presented our plans for the research project to the public advisory panel of
the Elizabeth Blackwell Institute. The panel members gave feedback about outcomes of most interest to
the public and suggested possible avenues for dissemination. On 6 October 2015, we presented our plans
for the research project to the UK Centre for Tobacco and Alcohol Studies Smokers Panel in Nottingham.
This interactive session involved a group of around 30 smokers, ex-smokers and health-care professionals.
We presented details of the outcomes we planned to study, the data we planned to use and the analysis
we expected to run. This presentation provided an opportunity to discuss with smokers what they knew
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about varenicline and where they got information on side effects. The panel was interested in more
evidence about the effects of varenicline in everyday clinical care, and possible side effects of varenicline.
On 5 June 2016, we presented our findings to the UK Centre for Tobacco and Alcohol Studies panel.
Study results
These presentations had a major impact on how we presented our results in the published papers.
In particular, it was clear that it was difficult for panel members to interpret multiple estimates from
the same study. Furthermore, providing the results on an intuitive scale helped make the results from
the study more accessible. We integrated this feedback into our presentation of the results in the
published papers.
Discussion and conclusions
The findings from the patient and public involvement helped inform our study and changed the way we
presented results, particularly around risk.
Strengths and limitations
A strength of our study is that we used the CPRD, which includes data from > 4.4 million patients
actively registered at general practices across the UK.15 These patients are likely to be representative
of patients prescribed smoking cessation medications in the UK. These patients are also more likely to
be representative of the population than participants recruited to RCTs. Furthermore, compliance with
treatment regimen is likely to be more representative of real-world compliance seen in primary care.
This fact means that our estimates of the effects of prescribing are likely to better reflect the effects
of prescribing smoking cessation medications in primary care. A drawback of this approach is that they
are likely to underestimate the effect of complying with treatment. The parameter is perhaps of most
interest to patients, who have the largest effect on compliance. Physicians, who have less influence
over compliance, may be more interested in the effect of issuing prescriptions for varenicline or NRT.
Where possible, we have used validated code lists to define the events used in this study. These lists
ensure that the events are well defined and have high sensitivity and specificity for detecting events.
For other outcomes, we constructed the code lists by using expert clinical review of search terms and
Read terms. We have uploaded the code lists used in this study to a repository for transparency and to
enable other researchers to reuse our code lists (https://github.com/nmdavies/varenicline-effectiveness).
The CPRD accurately records smoking status and GPs had financial incentives to record the smoking
status of their patients. Furthermore, they were incentivised to repeatedly ask smokers and former
smokers about their current smoking status. We used these records to determine patients’ smoking
status in the years after their first prescription.
Most of the data were complete. However, there were missing values of IMD and BMI. We addressed
this using multiple imputation for the multivariable-adjusted and propensity score regression models.
The imputation suggested that missing values of these covariates had little impact on our findings.
This similarity is partially because most of our covariate data and all of our prescription data were
complete. In a sensitivity analysis, we also investigated whether or not our results were robust to using
a multiple imputation model for smoking status after the first prescription. We found little evidence
that our results differed when we used multiple imputation.
We retrospectively analysed patients’ electronic medical records. This approach means that we had
a substantial follow-up period for each patient, both before they first received a smoking cessation
prescription (which we used to define baseline covariates) and after their first prescription (which we
used to define outcomes).
DISCUSSION
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A major limitation of observational studies is residual confounding. Confounding can occur if there
are baseline differences between patients given different treatments, in this case varenicline and NRT.
Patients who were prescribed varenicline were healthier in almost every way that we could measure,
although they were more likely to be male. We used multivariable-adjusted regression to control for
these differences. This approach assumes that the measured differences account for all differences
between patients given one treatment and another. This assumption is strong: that conditional on the
measured covariates, the patients were as good as randomised. Although we used a comprehensive set
of covariates, these variables are unlikely to have measured all differences between patients prescribed
NRT and varenicline. We addressed this limitation using propensity score matching and instrumental
variable analysis. The propensity score matching depends on similar assumptions to multivariable
regression (i.e. no residual confounding) but can help address imbalance where there are groups of
patients who were very unlikely to be given one of the treatments. Instrumental variable analysis
can estimate the causal effect in the presence of unmeasured confounding of the treatment outcome
association if the instrumental variable assumptions hold. The multivariable-adjusted and instrumental
variable estimates for the effectiveness analysis were similar, suggesting that they are unlikely to be
due to residual confounding. In contrast, for a number of the safety outcomes, there were substantial
differences between the multivariable-adjusted and instrumental variable analysis. These differences in
the results may indicate residual confounding.
We drew our sample from the general population of patients who were prescribed smoking cessation
medications in primary care. We included all smoking cessation treatments except bupropion. However,
very few patients received prescriptions for bupropion so this is unlikely to have caused selection bias
in our results.35 Furthermore, studies have found that bupropion is less effective than other treatments
and it is increasingly rarely prescribed.7
A significant limitation of our study is that we had little information on medication adherence or
over-the-counter use of NRT. We did not model treatment adherence or treatment duration. In this
study, we were aiming to replicate as closely as possible the intention-to-treat estimate in a RCT of
prescribing NRT or varenicline. Treatment adherence decisions are likely to be highly non-random
and may be related to the strength of addiction. This issue makes it difficult to estimate the causal
effect of adhering to treatment. Our instrumental variable affected prescribing decisions rather than
adherence. Varenicline is a prescription-only medicine. Therefore, we are likely to have complete
information about the amount of varenicline issued to our sample. However, individuals in our sample
are likely to have previously attempted to quit smoking using over-the-counter NRT. This could
bias our multivariable-adjusted estimate, for example if individuals prescribed varenicline were more
strongly addicted and had previously attempted to quit more frequently. Our instrumental variable
estimates could be biased, for example, if individuals who attend physicians preferring varenicline
have attempted to quit more frequently.
Finally, we estimated the effect of issuing prescriptions for NRT or varenicline, not the effect of
actually taking NRT or varenicline. This estimate is perhaps most relevant for clinicians who have
limited influence over treatment adherence. The effect of actually taking the medications is the
estimate most of interest to patients. However, we cannot directly address this hypothesis using the
models described in this project.
Areas of uncertainty
Our results provide relatively little evidence about the effects of smoking cessation medication on
outcomes after 4 years. Our follow-up is much longer than RCTs, which typically follow patients for
1 year. However, varenicline became available only in 2006, so the maximum possible follow-up in
our study was around 9 years. The follow-up for the vast majority of patients, who were prescribed
DOI: 10.3310/hta24090 Health Technology Assessment 2020 Vol. 24 No. 9
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Davies et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
37
varenicline after 2006, is much less than this. Future studies could use (1) a new extract of CPRD
data and (2) instrumental variable survival models to make more efficient use of these data.27
We had limited power to investigate whether or not the effects of these medications differed in
subgroups (e.g. older patients, patients with type 2 diabetes or patients diagnosed with cancer).
A larger sample of data could provide far more precise estimates of the effects of these drugs. The
CPRD covers only around 12% of the population. Therefore, a population sample could potentially
provide results that were 2.7 times as precise as the estimates presented in this study. We had limited
information about cancer stage and type. The information in the cancer registry could provide valuable
evidence about the effects of smoking cessation by cancer type and stage.
However, it is reassuring that large experimental studies and real-world observational studies suggest
that varenicline is both efficacious and effective in everyday clinical care. There was little evidence of
treatment effect heterogeneity.
We had limited power to detect effects on important clinical outcomes, particularly with the instrumental
variable analysis. The multivariable-adjusted analysis suggested that patients prescribed varenicline had
better outcomes very shortly after their first prescription. However, the instrumental variable estimates
suggested that residual confounding may drive these apparent benefits on clinical outcomes. There is
little experimental data on the long-term effects of smoking cessation. Therefore, most evidence about
the long- and medium-term effects of smoking cessation comes from observational studies, most of
which use methods similar to multivariable-adjusted regression.1 Our results suggest that multivariable-
adjusted regression may suffer from bias. Future studies could increase the precision of the results by
using a larger sample, or survival analysis to make more efficient use of the data.
DISCUSSION
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Chapter 7 Conclusions
Implications for service provision
Our results are consistent with large randomised trials and meta-analyses of smaller trials, suggesting
that varenicline is the most efficacious and effective method of smoking cessation.7,10 There may be a
need to update clinical guidance in the light of recent evidence.
Suggested research priorities
Trends in smoking cessation prescriptions
More evidence is needed about why prescribing of NRT and varenicline has fallen over the last decade.
One explanation may be because of increased use of e-cigarettes and over-the-counter use of NRT.
Alternatively, it may be because of changes to the funding and provision of addiction services. Our
results suggest that this decline is not due to the general decline in smoking rates because the rate
at which smokers receive NRT or varenicline prescriptions has fallen.
Long-term follow-up
Varenicline has only been available in the UK since 2006. This means that we have only a limited
observational follow-up, which, in our case, is a maximum of 9 years. Many of the health benefits
of smoking cessation are likely to accrue much later in life. It could be informative to prospectively
follow up patients treated with varenicline to compare their outcomes with patients treated with NRT
for much longer follow-up periods (10–20 years). It would be of methodological interest to compare
prospective estimates with retrospective estimates derived from cross-sectional and cohort studies.
Survival analysis with instrumental variables
Recent methodological papers have described estimators for using instrumental variables with survival
outcomes. Using survival outcomes could substantially increase the power of the study and could be
more informative than the additive structural mean models used in this report. Furthermore, it would
be informative to have more information about how these estimators perform on an applied example
with a large data set.
Comparing instrumental variable and multivariable-adjusted regression
One of the most significant limitations to observational analyses of electronic medical records is
residual confounding. Outside RCTs, patients are rarely treated at random. Researchers are rarely able
to measure all indications for treatment, which can result in bias. Instrumental variable analysis can
provide an alternative source of evidence based on different assumptions.36 However, instrumental
variable analysis can provide contradictory evidence to multivariable-adjusted regression using
the same data. During this project, we developed some tools that can potentially be used to assess
the relative plausibility of different methods.37 These methods use measured covariates to assess the
relative bias of instrumental variable and linear regression estimates using intuitive graphic plots.
However, more research is needed to guide clinicians and regulators about when estimates from
different methods should be used and preferred.
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